Literature DB >> 14997313

[Atorvastatin for primary prevention of cardiovascular events. ASCOT-LLA Study].

W März1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997313     DOI: 10.1007/s00108-003-1129-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  5 in total

1.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

2.  Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease.

Authors:  Stefano Sdringola; Keiichi Nakagawa; Yuko Nakagawa; S Wamique Yusuf; Fernando Boccalandro; Nizar Mullani; Mary Haynie; Mary Jane Hess; K Lance Gould
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

Review 3.  HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?

Authors:  Winfried März; Wolfgang Köenig
Journal:  J Cardiovasc Risk       Date:  2003-06

4.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

5.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.